[Comment] Transfemoral TMVR: turning promise into practice

Patients with symptomatic moderate-to-severe and severe mitral regurgitation who cannot undergo surgery or transcatheter edge-to-edge repair (TEER) have few treatment options. In The Lancet, Mayra E Guerrero and colleagues1 report 1-year outcomes of the ENCIRCLE pivotal study on a fully percutaneous, transfemoral, transseptal transcatheter mitral valve replacement (TMVR) system (SAPIEN M3; Edwards Lifesciences, Irvine, CA, USA), positioning this therapy as a potential third interventional option.